Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05972772
Other study ID # 26-23
Secondary ID
Status Not yet recruiting
Phase Phase 2/Phase 3
First received
Last updated
Start date March 20, 2024
Est. completion date August 31, 2026

Study information

Verified date March 2024
Source Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit
Contact Weerawat Phuklia, PhD
Phone +8562056581365
Email weerawat@tropmedres.ac
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Murine typhus is a disease caused by Rickettisa typhi, an obligate intracellular bacterium transmitted by rodent fleas. The disease has a worldwide distribution; however the true burden is unknown, related to its non-specific presentation and lack of access to diagnosis in many regions. A systematic review of untreated murine typhus based on observational studies of a total of 239 patients has estimated the mortality associated with the disease at between 0.4% and 3.6%. Scrub typhus is caused by Orientia tsutsugamushi and transmitted by the larval stage of chigger mites (Trombiculidae family). It has been estimated to affect at least one million people each year. A systematic review found varying reports of the mortality associated with untreated scrub typhus ranging from 0-70% (median 6%). Polymerase chain reaction (PCR) based diagnosis of rickettsial infections is only available in one centre (Mahosot Hospital) in Vientiane. A number of hospitals use a variety of point-of-care antibody tests to diagnose rickettsial infections however many of these have not been validated and they are of uncertain sensitivity and specificity. In 2006 results of a two year prospective study of 427 patients presenting to Mahosot Hospital with a febrile illness and negative blood cultures showed that 115 (27%) patients had an acute rickettsial infection, confirmed by serological testing. Among these patients, 41 were diagnosed with murine typhus and 63 with scrub typhus. Antibacterial agents with activity against rickettsial pathogens include doxycycline, azithromycin, chloramphenicol and rifampicin. Azithromycin is often reserved for pregnant women or children below the age of 8 years due to lasting concerns after the tetracycline-associated staining of growing bones and teeth in the past. Evidence is accumulating that doxycycline is superior to azithromycin for the treatment of rickettsial disease. Clinical treatment failures have occurred following azithromycin treatment of murine typhus. The relationship between rickettsial bacteria load and both disease severity and response to treatment has not been characterised. Rickettsial concentrations in blood are generally low, of the order of 210 DNA copies/mL blood for R. typhi and 284 DNA copies/mL blood for O. tsutsugamushi. At present, there is no standard antibiotic susceptibility testing (AST) method for R. typhi and O. tsutsugamushi. The gold standard method for AST for Rickettsia pathogens is the plaque assay which determines minimal inhibitory concentration (MICs) from the smallest antimicrobial concentration inhibiting rickettsial plaque forming unit formation. This method is laborious and time consuming, taking approximately 14-16 days based on species to yield a result. Molecular detection methods are useful for diagnosing patients infected with rickettsial pathogens and has been applied for antibiotic susceptibility testing. Antibiotic susceptibility testing based on DNA synthesis inhibition detecting by quantitative PCR (qPCR) for O. tsutsugamushi clinical isolates has been reported. However, the relationship between antibiotic susceptibility profiles and treatment response has not been studied. There is a need to develop a reliable ex vivo method to characterize the treatment response and compare susceptibility of R. typhi and O. tsutsugamushi to different agents.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 72
Est. completion date August 31, 2026
Est. primary completion date August 31, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age above or equal 18 years - Able to take oral medication - Agrees to stay in hospital for at least 36 hours and to attend for scheduled follow up visits - Written informed consent to participate in the study Exclusion Criteria: - Pregnancy (urine pregnancy test to be performed on women of childbearing age) - Previous allergic reaction to doxycycline or azithromycin - Received more than one dose of chloramphenicol, doxycycline, tetracycline, fluoroquinolones, rifampicin or azithromycin during the preceding week

Study Design


Intervention

Drug:
Doxycyclin
100-mg film-coated tablets; Pfizer
Azithromycin
250-mg capsules; Pfizer

Locations

Country Name City State
Lao People's Democratic Republic Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU) Vientiane Vientaine

Sponsors (2)

Lead Sponsor Collaborator
Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit Mahidol Oxford Tropical Medicine Research Unit

Country where clinical trial is conducted

Lao People's Democratic Republic, 

Outcome

Type Measure Description Time frame Safety issue
Other Evaluation the accuracy of the new brand RDT, Rickettsia IgG/IgM Combo (Lumiquick) compared to Scrub typhus Detect IgM Rapid System (Dipstick) (InBios) Sensitivity and specificity of Rickettsia IgG/IgM Combo (Lumiquick) compared to Scrub typhus Detect IgM Rapid System (Dipstick) (InBios) will be compared Day 0
Primary Rate of clearance of R. typhi or O. tsutsugamushi from peripheral blood of patients using serial qPCR measurement Measure of clearance or R. typhi or O. tsutsugamushi DNA assessed by serial qPCR measurements on the blood from murine typhus patients treated with either doxycycline or azithromycin. Rickettsia clearance rate will be estimated from serial qPCR measurement in each patient. The clearance rate is the slope of the initial log linear decline in qPCR estimated bacteria densities Within 72 hours after treatment
Secondary Area under the plasma concentration versus time curve (AUC) of doxycycline or azithromycin for the treatment of murine typhus or scrub typhus AUC of doxycycline or azithromycin versus time from zero to infinity in the treatment of murine typhus and scrub typhus will be estimated using a modelling approach Doxycycline: Based on plasma concentrations measure up to 96 hours after the last dose. Azithromycin: Based on plasma concentrations measure up to 2 weeks after the first dose.
Secondary Area under the intracellular concentration in the buffy coat versus time curve (AUC) of doxycycline or azithromycin for the treatment of murine typhus or scrub typhus AUC of doxycycline or azithromycin versus time from zero to infinity in the treatment of murine typhus and scrub typhus will be estimated using a modelling approach Doxycycline: Based on intracellular concentrations in the buffy coat measure up to 96 hours after the last dose. Azithromycin: Based on intracellular concentrations in Buffy coat measure up to 2 weeks after the first dose.
Secondary Peak plasma concentration (Cmax) of doxycycline or azithromycin for the treatment of murine typhus or scrub typhus Cmax of doxycycline or azithromycin versus time from zero to infinity in the treatment of murine typhus and scrub typhus will be estimated using a modelling approach Doxycycline: Based on plasma concentrations measure up to 96 hours after the last dose. Azithromycin: Based on plasma concentrations measure up to 2 weeks after the first dose.
Secondary Peak of the intracellular concentration (Cmax) in the buffy coat of doxycycline or azithromycin for the treatment of murine typhus or scrub typhus Cmax of doxycycline or azithromycin versus time from zero to infinity in the treatment of murine typhus and scrub typhus will be estimated using a modelling approach Doxycycline: Based on intracellular concentrations in the buffy coat measure up to 96 hours after the last dose. Azithromycin: Based on intracellular concentrations in the buffy coat measure up to 2 weeks after the first dose.
Secondary Time to peak plasma concentration (Tmax) of doxycycline or azithromycin for the treatment of murine typhus or scrub typhus Tmax of doxycycline or azithromycin versus time from zero to infinity in the treatment of murine typhus and scrub typhus will be estimated using a modelling approach Doxycycline: Based on plasma concentrations measure up to 96 hours after the last dose. Azithromycin: Based on plasma concentrations measure up to 2 weeks after the first dose.
Secondary Time to peak of the intracellular concentration (Tmax) in the buffy coat of doxycycline or azithromycin for the treatment of murine typhus or scrub typhus Tmax of doxycycline or azithromycin versus time from zero to infinity in the treatment of murine typhus and scrub typhus will be estimated using a modelling approach Doxycycline: Based on intracellular concentrations in the buffy coat measure up to 96 hours after the last dose. Azithromycin: Based on intracellular concentrations in the buffy coat measure up to 2 weeks after the first dose.
Secondary Time at doxycycline or azithromycin has lost half its maximum concentration (T1/2) for the treatment of murine typhus or scrub typhus T1/2 of doxycycline or azithromycin versus time from zero to infinity in the treatment of murine typhus and scrub typhus will be estimated using a modelling approach Doxycycline: Based on plasma concentrations measure up to 96 hours after the last dose. Azithromycin: Based on plasma concentrations measure up to 2 weeks after the first dose.
Secondary Time at doxycycline or azithromycin has lost half its maximum intracellular concentration (T1/2) for the treatment of murine typhus or scrub typhus T1/2 of doxycycline or azithromycin versus time from zero to infinity in the treatment of murine typhus and scrub typhus will be estimated using a modelling approach Doxycycline: Based on intracellular concentrations in the buffy coat measure up to 96 hours after the last dose. Azithromycin: Based on intracellular concentrations in the buffy coat measure up to 2 weeks after the first dose.
Secondary Fever clearance time in patients with scrub typhus or murine typhus treated with doxycycline or azithromycin Fever clearance time is defined as the time in hours from onset of antibiotic treatment, to the first Axillary temperature recording less than or equal 37.5°C, which then remains less than or equal 37.5°C for 24 hours First 7 days after treatment
Secondary Frequency of serious adverse events (SAEs) after treatment SAEs will be defined using the Common Toxicity Criteria (v5.0) of the US National Cancer Institute Day 0 to day 28
See also
  Status Clinical Trial Phase
Recruiting NCT05568953 - An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity Phase 2
Completed NCT04568889 - Minnesota COVID-19 Testing Project N/A
Completed NCT06063330 - Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects Phase 1
Completed NCT01198925 - Assessment of the Optimal Dosing of Piperacillin-tazobactam in Intensive Care Unit Patients: Extended Versus Continuous Infusion Phase 4
Completed NCT05063812 - Performance of a Remote Monitoring Program for Patients Diagnosed With COVID-19
Not yet recruiting NCT03636711 - Antibiotic Stewardship in Infectious Disease Departement
Completed NCT03457688 - Effect of Prebiotic Fructans to Reduce Number of Febrile Infections in Children N/A
Completed NCT03241355 - Prebiotic Fructans on the Incidence of Acute Infectious Diseases in Children N/A
Terminated NCT05420077 - Safety and Immunogenicity of RVM-V001 in Healthy Individuals Previously Vaccinated With BNT162b2 and mRNA-1273 Phase 1
Completed NCT04084106 - Effects of Phenoximethylpenicillin, Amoxicillin and Amoxicillin-clavulanic Acid on the Gut Microbiota Phase 4
Recruiting NCT05013944 - AnovaOS Network Powered Patient Registry
Completed NCT03893279 - Perception of Smell and Taste During Antibiotic Treatment
Active, not recruiting NCT05619770 - Study to Evaluate Pharmacokinetics, Safety & Tolerability of 101-PGC-005 in Healthy, Adult, Human Subjects Phase 1
Completed NCT01772901 - Brief Influenza Vaccine Education to Pregnant Women N/A
Completed NCT05413772 - Temocillin in ESBL-Enterobacteriaceae Infections
Completed NCT04319328 - Is Cefazolin, Ceftazidime and Ciprofloxacin Dosing Optimal in Hemodialysis Patients?
Completed NCT04613271 - Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia Phase 3
Completed NCT03239665 - Vaccination Education Through Pharmacists and Senior Centers (VEPSC) N/A
Completed NCT03224026 - Validation of a Proteomic Signature and Assessment of Viremia in Children With Fever Without Source
Not yet recruiting NCT06102070 - Genetic Susceptibility to Severe Infections